PureTech Takes On Roche With Improved IPF Drug
Modified Version Of Esbriet Seems Safer
The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.
You may also be interested in...
Financing Snapshot: Seattle biotech claims its targeted, inhalable versions of Esbriet and Ofev, both oral IPF drugs, may offer better tolerability and stronger efficacy than established products.
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.
Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.